Advertisement

Medicinal Chemistry Research

, Volume 26, Issue 12, pp 3228–3239 | Cite as

In silico studies on 2-substituted phenol quinazoline derivatives as RET receptor tyrosine kinase antagonists

  • Swapnil P. Bhujbal
  • Pavithra K. Balasubramanian
  • Seung Joo Cho
Original Research
  • 120 Downloads

Abstract

Rearranged during transfection is a transmembrane receptor tyrosine kinase. It is involved in medullary thyroid cancer and lung adenocarcinoma in humans. In this work, molecular docking and three-dimensional quantitative structure–activity relationship studies were performed on recently reported series of two-substituted phenol quinazoline derivatives as rearranged during transfection inhibitors. Docking study identified key active site residues such as Ala807, Lys758, Leu802, Leu730, Tyr806, Ala756, Val804, Asp892, and Glu775 that participate in the inhibition of rearranged during transfection. A reasonable comparative molecular field analysis (q 2 = 0.592, optimal number of components = 4, r 2 = 0.921) and comparative molecular similarity indices analysis (q 2 = 0.580, optimal number of components = 6, r 2 = 0.963) models were generated in three-dimensional quantitative structure–activity relationship study. Various validation techniques such as external test set validation, bootstrapping analysis, and progressive scrambling were carried out to check the predictive ability of the obtained models. The validated models resulted in acceptable statistical values and proved to be predictive and robust. comparative molecular similarity indices analysis model was selected as the final model based on the reasonable statistical values of q 2, r 2, standard error of estimate, and r 2 pred. The contour maps analysis of comparative molecular similarity indices analysis model revealed the favorable regions to enhance the inhibitory activity of compounds. R1 and R4 positions were favorable for bulky substitution. Hydrophilic and negative substitutions at R5 position were favorable. Thus results of our study can provide insights in the designing potent and selective rearranged during transfection kinase inhibitors.

Keywords

RET Molecular docking CoMFA CoMSIA RET kinase inhibitors 

Notes

Acknowledgements

This work was supported by the National Research Foundation of Korea grant (MRC, 2015-009070) funded by the Korea government (MSIP).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Airaksinen MS, Titievsky A, Saarma M (1999) GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 13:313–325CrossRefPubMedGoogle Scholar
  2. Arighi E, Borrello MG, Sariola H (2005) RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16:441–467CrossRefPubMedGoogle Scholar
  3. Brandt W et al. (2010) Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl) nicotinonitrile scaffold. Eur J Med Chem 45:2919–2927CrossRefPubMedGoogle Scholar
  4. Carlomagno F et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326–334CrossRefPubMedGoogle Scholar
  5. Carlomagno F et al. (2009) Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocr Relat Cancer 16:233–241CrossRefPubMedGoogle Scholar
  6. Cincinelli R et al. (2008) Synthesis, modeling, and RET protein kinase inhibitory activity of 3-and 4-substituted β-carbolin-1-ones. J Med Chem 51:7777–7787CrossRefPubMedGoogle Scholar
  7. Clark M, Cramer RD, Van Opdenbosch N (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem 10:982–1012CrossRefGoogle Scholar
  8. Cramer III RD (1993) Partial least squares (PLS): its strengths and limitations. Perspect Drug Discov Des 1:269–278CrossRefGoogle Scholar
  9. Cramer RD et al. (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 7:18–25CrossRefGoogle Scholar
  10. Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967CrossRefPubMedGoogle Scholar
  11. Cranston AN et al. (2006) RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 66:10179–10187CrossRefPubMedGoogle Scholar
  12. DiMagno SG, Sun H (2006) The strength of weak interactions: aromatic fluorine in drug design. Curr Top Med Chem 6:1473–1482CrossRefPubMedGoogle Scholar
  13. Dinér P et al. (2012) Preparation of 3-substituted-1-isopropyl-1 H-pyrazolo [3, 4-d] pyrimidin-4-amines as RET kinase inhibitors. J Med Chem 55:4872–4876CrossRefPubMedGoogle Scholar
  14. Drilon A et al. (2013) Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630–635CrossRefPubMedPubMedCentralGoogle Scholar
  15. Dunna NR et al. (2015) High affinity pharmacological profiling of dual inhibitors targeting RET and VEGFR2 in inhibition of kinase and angiogeneis events in medullary thyroid carcinoma. J Cancer Prev 16:7089–7095Google Scholar
  16. Fallahi P et al. (2015) Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Dev Ther 9:3459Google Scholar
  17. Gaumann AK et al. (2016) Receptor tyrosine kinase inhibitors: are they real tumor killers? Int J Cancer 138:540–554CrossRefPubMedGoogle Scholar
  18. Gautschi O et al. (2013) A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 8:e43–e44CrossRefPubMedGoogle Scholar
  19. Hansford JR, Mulligan LM (2000) Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis. J Med Genet 37:817–827CrossRefPubMedPubMedCentralGoogle Scholar
  20. Horiike A et al. (2016) Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. Lung Cancer 93:43–46CrossRefPubMedGoogle Scholar
  21. Hubbard SR, Miller WT (2007) Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19:117–123CrossRefPubMedPubMedCentralGoogle Scholar
  22. Huey R et al. (2007) A semiempirical free energy force field with charge‐based desolvation. J Comput Chem 28:1145–1152CrossRefPubMedGoogle Scholar
  23. Ibáñez CF (2013) Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol 5:a009134CrossRefPubMedPubMedCentralGoogle Scholar
  24. Jeong W-J et al. (2011) Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther 12:458–465CrossRefPubMedGoogle Scholar
  25. Kamath S, Buolamwini JK (2003) Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem 46:4657–4668CrossRefPubMedGoogle Scholar
  26. Kilkenny C et al. (1996) GDNF signaling through the Ret receptor tyrosine kinase. Nature 381:789–793CrossRefPubMedGoogle Scholar
  27. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146CrossRefPubMedGoogle Scholar
  28. Knowles PP et al. (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577–33587CrossRefPubMedGoogle Scholar
  29. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134CrossRefPubMedPubMedCentralGoogle Scholar
  30. Li Y-P et al. (2013) 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. J Mol Graph Model 41:61–67CrossRefPubMedGoogle Scholar
  31. Meng S et al. (2016) Systematic analysis of tyrosine kinase inhibitor response to RET gatekeeper mutations in thyroid cancer. Mol Inform 35:495–505CrossRefPubMedGoogle Scholar
  32. Moccia M et al. (2015) Identification of novel small molecule inhibitors of oncogenic RET kinase. PLoS One 10:e0128364CrossRefPubMedPubMedCentralGoogle Scholar
  33. Mologni L et al. (2010) Synthesis, structure–activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem 18:1482–1496CrossRefPubMedGoogle Scholar
  34. Newton R et al. (2016) The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Eur J Med Chem 112:20–32CrossRefPubMedPubMedCentralGoogle Scholar
  35. Norinder U (1998) Recent progress in CoMFA methodology and related techniques. In: Kubinyi H, Folkers G and Martin YC (eds) 3D QSAR in drug design: recent advances. Springer Netherlands, Sweden, p 25–39Google Scholar
  36. Phay JE, Shah MH (2010) Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16:5936–5941CrossRefPubMedGoogle Scholar
  37. Pratim Roy P et al. (2009) On two novel parameters for validation of predictive QSAR models. Molecules 14:1660–1701CrossRefPubMedGoogle Scholar
  38. Roskoski R (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26–48CrossRefPubMedGoogle Scholar
  39. Santoro M et al. (2004) Minireview: RET: normal and abnormal functions. Endocrinology 145:5448–5451CrossRefPubMedGoogle Scholar
  40. Sartini S et al. (2014) Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies. J Med Chem 57:1225–1235CrossRefPubMedGoogle Scholar
  41. Watson AJ et al. (2016) Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. F1000Researcho, 5.Google Scholar
  42. Wold S et al. (1984) The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comput 5:735–743CrossRefGoogle Scholar
  43. Yoon H et al. (2015) A pyrazolo [3, 4-d] pyrimidin-4-amine derivative containing an isoxazole moiety is a selective and potent inhibitor of RET gatekeeper mutants. J Med Chem 59:358–373CrossRefPubMedGoogle Scholar
  44. Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer 8:161–173CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Biomedical Sciences, College of MedicineChosun UniversityGwangjuRepublic of Korea
  2. 2.Department of Cellular, Molecular Medicine, College of MedicineChosun UniversityGwangjuRepublic of Korea

Personalised recommendations